Livagen vs Pancragen
Moderate Research vs Moderate Research
compatible Different organ targets; can be used in comprehensive bioregulator protocols.
Molecular Data
Livagen Pancragen
Weight 432 Da 576 Da
Half-life Not established Not established
Chain 4 amino acids 4 amino acids
Type Tetrapeptide bioregulator Tetrapeptide bioregulator
Key Benefits
Livagen
01 Significant hepatoprotective properties
02 Decondenses chromatin to activate genes
03 Restores liver function in hepatitis
04 Normalizes immune status
05 Improves antioxidant status
06 Activates ribosomal gene expression
07 Maximum effects occur during aging
08 Boosts protein synthesis and cell activity
Pancragen
01 Corrects impaired glucose tolerance
02 Normalizes insulin levels
03 Normalizes C-peptide levels
04 Improves endocrine pancreatic function
05 Supports pancreatic cell differentiation
06 Regulates melatonin expression
07 Reduces metabolic syndrome incidence
08 Upregulates key pancreatic transcription factors
Dosing Protocols
Livagen
10-20 mg daily / Daily for 10-20 days per cycle
Research protocol 10 mg Daily for 10 days
Pancragen
10-20mg daily / Daily for 10-20 days per cycle
Research protocol 0.05 mg/kg Daily for 10 days
Side Effects
Livagen
Generally well-tolerated
Minimal side effects reported
Pancragen
Generally well-tolerated
Minimal side effects reported
Contraindications
Active liver emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Active pancreatic emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Type 1 diabetes (consult physician)
Research Evidence
Livagen Pancragen
Status Moderate Research Moderate Research
References 4 studies 4 studies
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.